STOCK TITAN
  1. Home
  2. Sec-filings
  3. CMMB
  4. [Form 3] Chemomab Therapeutics Ltd. Initial Statement of Beneficial Ownership

Chemomab (CMMB) CEO discloses ADS, RSU and stock option stakes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. director and Chief Executive Officer Mor George Adi filed an initial ownership report showing his holdings in American Depositary Shares (ADSs), stock options, and RSUs. This Form 3 does not reflect new buying or selling activity; it establishes his existing equity position.

He holds options over 32,925 ADSs at an exercise price of $5.94 expiring in 2028 and options over 109,718 ADSs at $5.16 expiring in 2033, both directly. Indirectly, his spouse holds options over 8,431 ADSs at $3.20 expiring in 2026. Direct ADS holdings include 79,268, 31,712 and 18,750 shares, with an additional 50,059 ADSs held indirectly by his spouse. Footnotes describe RSU grants with quarterly vesting schedules through 2028 and 2029, highlighting that a portion of his equity exposure will vest over time rather than all at once.

Positive

  • None.

Negative

  • None.
Insider Mor George Adi
Role Chief Executive Officer
Type Security Shares Price Value
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding Stock option (right to buy American Depositary Shares) -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
holding American Depositary Shares -- -- --
Holdings After Transaction: Stock option (right to buy American Depositary Shares) — 32,925 shares (Direct); Stock option (right to buy American Depositary Shares) — 8,431 shares (Indirect, Securities held by the Reporting Person's spouse.); American Depositary Shares — 79,268 shares (Direct); American Depositary Shares — 50,059 shares (Indirect, Securities held by the Reporting Person's spouse.)
Footnotes (1)
  1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029. The options reported in this row were granted to the Reporting Person by the Issuer on March 15, 2018, and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 1, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 1, 2027. The options reported in this row were granted to the Reporting Person's spouse by the Issuer on October 28, 2016, are fully vested and exercisable as of the date of this report.
Direct ADS options at $5.94 32,925 underlying ADSs Stock options exercisable at $5.94 expiring March 15, 2028
Direct ADS options at $5.16 109,718 underlying ADSs Stock options exercisable at $5.16 expiring August 7, 2033
Indirect ADS options at $3.20 8,431 underlying ADSs Spouse-held stock options at $3.20 expiring October 27, 2026
Direct ADS holdings 79,268 ADSs American Depositary Shares held directly as of March 18, 2026 entry
Additional indirect ADS holdings 50,059 ADSs American Depositary Shares held by spouse as of March 18, 2026 entry
RSU vesting completion date October 1, 2028 All RSUs from November 18, 2024 grant exercisable by this date
American Depositary Shares financial
"The American Depositary Shares reported in this row consist of restricted share units"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
restricted share units ("RSUs") financial
"consist of restricted share units ("RSUs") that were granted to the Reporting Person"
fully vested and exercisable financial
"were granted to the Reporting Person by the Issuer on March 15, 2018, and are fully vested and exercisable"
quarterly installments of 6.25% financial
"thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs"
stock option (right to buy American Depositary Shares) financial
"security_title": "Stock option (right to buy American Depositary Shares)""
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Mor George Adi
(Last)(First)(Middle)
C/O CHEMOMAB THERAPEUTICS LTD.
10 HABARZEL ST., BUILDING C, 10TH FLOOR
(Street)
TEL AVIV615810
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares79,268D
American Depositary Shares50,059ISecurities held by the Reporting Person's spouse.
American Depositary Shares(1)31,712D
American Depositary Shares(2)18,750D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy American Depositary Shares) (3)03/15/2028American Depositary Shares32,925$5.94D
Stock option (right to buy American Depositary Shares) (4)08/07/2033American Depositary Shares109,718$5.16D
Stock option (right to buy American Depositary Shares) (5)10/27/2026American Depositary Shares8,431$3.2ISecurities held by the Reporting Person's spouse.
Explanation of Responses:
1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on November 18, 2024, and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.
2. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on July 1, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.
3. The options reported in this row were granted to the Reporting Person by the Issuer on March 15, 2018, and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 1, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 1, 2027.
5. The options reported in this row were granted to the Reporting Person's spouse by the Issuer on October 28, 2016, are fully vested and exercisable as of the date of this report.
Remarks:
This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.
/s/ Adi Mor04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Chemomab (CMMB) CEO Mor George Adi report in this Form 3?

The Form 3 shows Mor George Adi’s existing holdings of Chemomab ADSs, stock options, and RSUs. It discloses his direct and spouse-held positions, establishing baseline ownership rather than recording new purchases or sales.

How many Chemomab (CMMB) ADS options does the CEO hold directly?

He reports stock options over 32,925 ADSs at $5.94 per share expiring in 2028 and 109,718 ADSs at $5.16 expiring in 2033. Both option grants are held directly and reflect unexercised, outstanding awards.

What Chemomab (CMMB) equity is held indirectly through the CEO’s spouse?

Indirect holdings include options over 8,431 ADSs at a $3.20 exercise price expiring in 2026, plus 50,059 ADSs. These positions are described as securities held by the reporting person’s spouse, rather than directly by the CEO.

Does this Chemomab (CMMB) Form 3 show any insider buying or selling?

No, the filing lists holdings only and transaction codes are unknown with no share amounts reported as trades. It functions as an initial ownership snapshot, not as a record of open-market purchases or sales.

What RSU vesting schedules are disclosed for Chemomab (CMMB) CEO Mor George Adi?

Footnotes state RSUs granted in November 2024 vest 25% on October 1, 2025, then in 12 quarterly installments of 6.25% through October 1, 2028. RSUs granted July 1, 2025 follow a similar schedule through April 10, 2029.